BioLineRx Overview
- Year Founded
-
2003
- Status
-
Public
- Employees
-
24
- Stock Symbol
-
BLRX
- Investments
-
5
BioLineRx General Information
Description
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
Contact Information
Website
www.biolinerx.comCorporate Office
- Modi'in Technology Park
- 2 HaMa'ayan Street
- Modiin 7177871
- Israel
Corporate Office
- Modi'in Technology Park
- 2 HaMa'ayan Street
- Modiin 7177871
- Israel
BioLineRx Timeline
BioLineRx Stock Performance
As of 16-Nov-2026, BioLineRx’s current market cap is $9.3M with 2.99B shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $9.3M | 2.99B | 3.57M |
BioLineRx Financials Summary
As of 30-Jun-2026, BioLineRx has a trailing 12-month revenue of $1.39M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 8,738 | (1,287) | 22,553 | 101,865 |
| Revenue | 1,392 | 1,180 | 28,940 | 4,800 |
| EBITDA | (9,459) | (1,376) | 2,098 | (59,093) |
| Net Income | (6,989) | (1,175) | (9,221) | (60,614) |
| Total Assets | 33,480 | 40,905 | 38,906 | 63,925 |
| Total Debt | 7,941 | 10,150 | 15,040 | 11,591 |
BioLineRx Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
BioLineRx Comparisons
Industry
Financing
Details
BioLineRx Competitors (32)
One of BioLineRx’s 32 competitors is AnTolRx, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| AnTolRx | Formerly VC-backed | Cambridge, MA | ||||
| Dendreon | Formerly VC-backed | Seal Beach, CA | ||||
| X4 Pharmaceuticals | Formerly VC-backed | Boston, MA | ||||
| Rein Therapeutics | Formerly VC-backed | Austin, TX | ||||
| Sagimet Biosciences | Formerly VC-backed | Foster City, CA |
BioLineRx Patents
BioLineRx Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025224720-A1 | Methods of selecting treatment regimen against solid tumors | Pending | 24-Apr-2024 | ||
| WO-2025032571-A1 | Unit dosage forms and methods comprising bl8040 for intravenous administration | Inactive | 07-Aug-2023 | ||
| JP-2026513170-A | Methods for recruiting hematopoietic progenitor cells | Pending | 26-Mar-2023 | ||
| AU-2024241828-A1 | Methods of hematopoietic precursor cells mobilization | Pending | 26-Mar-2023 | ||
| EP-4687960-A1 | Methods of hematopoietic precursor cells mobilization | Pending | 26-Mar-2023 | A61P35/02 |
BioLineRx Signals
BioLineRx Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
BioLineRx Investments & Acquisitions (5)
BioLineRx’s most recent deal was a Joint Venture with GLIX1. The deal was made on 29-Sep-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| GLIX1 | 29-Sep-2025 | Joint Venture | Drug Discovery | ||
| Biokine | 03-Oct-2018 | Corporate | Drug Discovery | ||
| Agalimmune | 23-Mar-2017 | Merger/Acquisition | Biotechnology | ||
| iPharma Labs | 25-Aug-2016 | Joint Venture | Drug Discovery | ||
| Biokine | Merger/Acquisition | Drug Discovery |
BioLineRx ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
BioLineRx Exits (1)
BioLineRx’s most recent exit was on 25-Aug-2016 from iPharma Labs. The exit was categorized as with 2 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| iPharma Labs | 25-Aug-2016 | Completed |
|
BioLineRx Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Biokine | Rehovot, Israel | 2000 |
BioLineRx FAQs
-
When was BioLineRx founded?
BioLineRx was founded in 2003.
-
Where is BioLineRx headquartered?
BioLineRx is headquartered in Modiin, Israel.
-
What is the size of BioLineRx?
BioLineRx has 24 total employees.
-
What industry is BioLineRx in?
BioLineRx’s primary industry is Drug Discovery.
-
Is BioLineRx a private or public company?
BioLineRx is a Public company.
-
What is BioLineRx’s stock symbol?
The ticker symbol for BioLineRx is BLRX.
-
What is the current market cap of BioLineRx?
The current market capitalization of BioLineRx is $9.3M.
-
What is BioLineRx’s current revenue?
The trailing twelve month revenue for BioLineRx is $1.39M.
-
Who are BioLineRx’s competitors?
AnTolRx, Dendreon, X4 Pharmaceuticals, Rein Therapeutics, and Sagimet Biosciences are some of the 32 competitors of BioLineRx.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process